A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients

Psychiatry Research - Neuroimaging

Volumn 194, Issue 1, 2011, Pages 79-84

  Mané, Anna ^a   Gallego, Judith ^b   Lomeña, Francisco ^c,d   Mateos, Jose Javier ^e   Fernandez Egea, Emilio ^f,g   Horga, Guillermo ^c,h   Cot, Albert ^b,i   Pavia, Javier ^b,c,i   Bernardo, Miguel ^c,j   Parellada, Eduard ^c,j  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e Centre de Imatge Molecular   (Spain)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST   (United Kingdom)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^j CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

more..

Author keywords

Basal ganglia; Longitudinal; Negative; Outcome

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 2 CARBOMETHOXY 3 (4 IODOPHENYL) N (3 FLUOROPROPYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BINDING; RADIATION DOSE; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATE CORTEX; SYMPTOMATOLOGY;

ADULT; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; OCCIPITAL LOBE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES; YOUNG ADULT;

EID: 80053384052     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.03.004     Document Type: Article

References (36)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American Journal of Psychiatry 1998, 155:761-767.
2. Ballmaier M., Schlagenhauf F., Toga A.W., Gallinat J., Koslowski M., Zoli M., Hojatkashani C., Narr K.L., Heinz A. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophrenia Research 2008, 106:140-147.
3. Booij J., Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35:424-438.
4. Buchsbaum M.S., Shihabuddin L., Brickman A.M., Miozzo R., Prikryl R., Shaw R., Davis K. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophrenia Research 2003, 64:53-62.
5. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. The American Journal of Psychiatry 1991, 148:1474-1486.
6. Drew A.E., Werling L.L. Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophrenia Research 2003, 65:47-55.
7. First, M. B., Spitzer R. S., Gibbon M., Williams J. B. W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV), Spanish adaptation. Masson, 1999.
8. Glenthoj A., Glenthoj B.Y., Mackeprang T., Pagsberg A.K., Hemmingsen R.P., Jernigan T.L., Baare W.F. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research: Neuroimaging 2007, 154:199-208.
9. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. The American Journal of Psychiatry 1998, 155:1711-1717.
10. Hantraye P., Brownell A.L., Elmaleh D., Spealman R.D., Wullner U., Brownell G.L., Madras B.K., Isacson O. Dopamine fiber detection by [11C]-CFT and PET in a primate model of parkinsonism. Neuroreport 1992, 3:265-268.
11. Harrison G., Hopper K., Craig T., Laska E., Siegel C., Wanderling J., Dube K.C., Ganev K., Giel R., an der Heiden W., Holmberg S.K., Janca A., Lee P.W., León C.A., Malhotra S., Marsella A.J., Nakane Y., Sartorius N., Shen Y., Skoda C., Thara R., Tsirkin S.J., Varma V.K., Walsh D., Wiersma D. Recovery from psychotic illness: a 15- and 25-year international follow-up study. The British Journal of Psychiatry 2001, 178:506-517.
12. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., Ruotsalainen U. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995, 346:1130-1131.
13. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. The American Journal of Psychiatry 2005, 162:2233-2245.
14. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophrenia Bulletin 2009, 35:549-562.
15. Juckel G., Schlagenhauf F., Koslowski M., Wustenberg T., Villringer A., Knutson B., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage 2006, 29:409-416.
16. Kay S.R., Fiszbein A., Vital-Herne M., Fuentes L.S. The Positive and Negative Syndrome Scale-Spanish adaptation. The Journal of Nervous and Mental Disease 1990, 178:510-517.
17. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49:603-615.
18. Kubicki M., Shenton M.E., Salisbury D.F., Hirayasu Y., Kasai K., Kikinis R., Jolesz F.A., McCarley R.W. Voxel-based morphometric analysis of gray matter in first episode schizophrenia. NeuroImage 2002, 17:1711-1719.
19. Laakso A., Vilkman H., Alakare B., Haaparanta M., Bergman J., Solin O., Peurasaari J., Rakkolainen V., Syvalahti E., Hietala J. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. The American Journal of Psychiatry 2000, 157:269-271.
20. Laakso A., Bergman J., Haaparanta M., Vilkman H., Solin O., Syvalahti E., Hietala J. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophrenia Research 2001, 52:115-120.
21. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 1996, 20(93):9235-9240.
22. Laruelle M., van Abi-Dargham A., D.C., Gil R., D'Souza D.C., Krystal J., Seibyl J., Baldwin R., Innis R. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biological Psychiatry 2000, 47:371-379.
23. Li S., Kim K.Y., Kim J.H., Kim J.H., Park M.S., Bahk J.Y., Kim M.O. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neuroscience Letters 2004, 363:29-32.
24. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berlin) 1987, 91:415-433.
25. Lieberman J.A., Sheitman B.B., Kinon B.J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 1997, 17:205-229.
26. Lindstrom L.H., Gefvert O., Hagberg G., Lundberg T., Bergstrom M., Hartvig P., Langstrom B. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biological Psychiatry 1999, 46:681-688.
27. Lyon G.J., Abi-Dargham A., Moore H., Lieberman J.A., Javitch J.A., Sulzer D. Presynaptic regulation of dopamine transmission in schizophrenia. Schizophrenia Bulletin 2011, 37(1):108-117.
28. Mané A., Falcon C., Mateos J.J., Fernandez-Egea E., Horga G., Lomena F., Bargallo N., Prats-Galino A., Bernardo M., Parellada E. Progressive gray matter changes in first episode schizophrenia: a 4-year longitudinal magnetic resonance study using VBM. Schizophrenia Research 2009, 114:136-143.
29. Mateos J.J., Lomena F., Parellada E., Font M., Fernandez E., Pavia J., Prats A., Pons F., Bernardo M. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berlin) 2005, 181:401-406.
30. Mateos J.J., Lomena F., Parellada E., Mireia F., Fernandez-Egea E., Pavia J., Prats A., Pons F., Bernardo M. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berlin) 2007, 191:805-811.
31. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neuroscience 2002, 5:267-271.
32. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., Bachneff S., Cumming P., Diksic M., Dyve S.E., Etienne P., Evans A.C., Lal S., Shevell M., Savard G., Wong D.F., Chouinard G., Gjedde A. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:11651-11654.
33. Schmitt G.J., Meisenzahl E.M., Frodl T., La F.C., Hahn K., Moller H.J., Dresel S. The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. Journal of Psychopharmacology 2005, 19:488-493.
34. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
35. Sjöholm H., Bratlid T., Sundsfjord J. 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berlin) 2004, 173:27-31.
36. van Dyck C.H., Seibyl J.P., Malison R.T., Laruelle M., Zoghbi S.S., Baldwin R.M., Innis R.B. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. The American Journal of Geriatric Psychiatry 2002, 10:36-43.